Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 perioperative dostarlimab versus standard of care in resectable dMMR/MSI-H colon cancer
NL-OMON59649Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in colon adenocarcinoma and colon cancer comparing Perioperative dostarlimab with Standard of care (2 arms). Primary endpoint: Event-free survival by blinded independent central review. Started Dec 2023; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on NL-OMON59649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59649.